Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
56.03
+1.14 (2.08%)
Jan 30, 2025, 4:00 PM EST - Market closed
Exact Sciences Revenue
Exact Sciences had revenue of $708.66M in the quarter ending September 30, 2024, with 12.78% growth. This brings the company's revenue in the last twelve months to $2.69B, up 11.91% year-over-year. In the year 2023, Exact Sciences had annual revenue of $2.50B with 19.93% growth.
Revenue (ttm)
$2.69B
Revenue Growth
+11.91%
P/S Ratio
3.81
Revenue / Employee
$407,928
Employees
6,600
Market Cap
10.37B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.50B | 415.49M | 19.93% |
Dec 31, 2022 | 2.08B | 317.19M | 17.95% |
Dec 31, 2021 | 1.77B | 275.70M | 18.49% |
Dec 31, 2020 | 1.49B | 615.10M | 70.19% |
Dec 31, 2019 | 876.29M | 421.83M | 92.82% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.95B |
EXAS News
- 9 days ago - Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium - Business Wire
- 9 days ago - New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients - Business Wire
- 17 days ago - Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market - Benzinga
- 17 days ago - Exact Sciences Announces Preliminary Fourth Quarter 2024 Results - Business Wire
- 4 weeks ago - Exact Sciences to Participate in J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates - GlobeNewsWire
- 2 months ago - Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript) - Seeking Alpha
- 2 months ago - Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript) - Seeking Alpha